Survey Result Findings - SetPoint RESET-RA

Menu

Qualify for a Medical Study for Rheumatoid Arthritis

Treatment
About
FAQ
Learn More

Close Menu

CAUTION – Investigational device. Limited by United States law to investigational use.

By using our website you agree to our privacy policy.
The RESET-RA Study is sponsored by SetPoint Medical Inc.
Located at 25101 Rye Canyon Loop, Valencia, CA 91355.
Copyright © 2024 SetPoint Medical Inc. All rights reserved
CLM-500 Rev I

Biologic and targeted synthetic DMARDs include:

Abatacept (Orencia)
Adalimumab (Humira)
Anakinra (Kineret)
Baricitinib (Olumiant)
Certolizumab (Cimzia)
Etanercept (Enbrel)
Golimumab (Simponi)
Infliximab (Remicade)
Rituximab (Rituxan, MabThera)
Sarilumab (Kevzara)
Tocilizumab (Actemra)
Tofacitiniib (Xeljanz, Xeljanz XR)
Upadacitinib (Rinvoq)

Conventional synthetic DMARDs include:

Hydroxychloroquine (Plaquenil)
Leflunomide (Arava)
Methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo)
Sulfasalazine (Azulfidine)